Human Cell Research Publications

Publications

Published articles propel biomedical research forward by explaining the unknown, promoting discovery and laying the foundation for future scientific inquiry. AllCells greatly appreciates the researchers and institutions that have cited AllCells products in their high-impact articles, for playing a vital role in this type of research is at the center of AllCells purpose. Journals and publications that cite AllCells products have been compiled below. Sort by cell type and/or tissue type to find articles related to your research.

HIV-1 is Restricted Prior to Integration in Primary Cord-Derived Human CD34+ Cells

Daniel O. Griffin and Stephen Goff

JVI Accepted Manuscript Posted Online 20 May 2015

Certain cells have the ability to block retroviral infection at specific stages of the viral cycle by the activities of well-characterized factors and transcriptional silencing machinery. Infection of murine stem cells (MSCs) by the murine leukemia viruses (MLVs) is profoundly blocked post-integration by transcriptional silencing.

Human Mesenchymal Stromal/Stem Cell-Mediated Bone Marrow Organization

Yasuo Miura , Tatsuo Ichinohe, Taira Maekawa

Japanese Journal of Transfusion and Cell Therapy Vol. 61 (2015) No. 5 p. 489-490

Mesenchymal stromalstem cells (MSCs) in bone marrow differentiate into cellular components of the hematopoietic cell niche, including osteogenic cells. A human MSC transplantation into mice (xenotransplantation model) is one of the best available in vivo models to recapitulate MSC-mediated bone and bone marrow organization.

Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells

Ayal Hendel, Rasmus O Bak, Joseph T Clark, Andrew B Kennedy, Daniel E Ryan, Subhadeep Roy, Israel Steinfeld, Benjamin D Lunstad, Robert J Kaiser, Alec B Wilkens, Rosa Bacchetta, Anya Tsalenko, Douglas Dellinger, Laurakay Bruhn & Matthew H Porteus

Nature Biotechnology 33, 985–989 (2015), Published online 29 June 2015

CRISPR-Cas-mediated genome editing relies on guide RNAs that direct site-specific DNA cleavage facilitated by the Cas endonuclease. Here we report that chemical alterations to synthesized single guide RNAs (sgRNAs) enhance genome editing efficiency in human primary T cells and CD34+ hematopoietic stem and progenitor cells.

Agonist antibody that induces human malignant cells to kill one another

Kyungmoo Yeaa , Hongkai Zhangb , Jia Xieb , Teresa M. Jonesb , Chih-Wei Linb , Walter Francesconic , Fulvia Bertond , Mohammad Fallahie , Karsten Sauerb,f, and Richard A. Lernerb

Proceedings of the National Academy of Sciences of the United States of America, Contributed by Richard A. Lerner, September 25, 2015

An attractive, but as yet generally unrealized, approach to cancer therapy concerns discovering agents that change the state of differentiation of the cancer cells. Recently, we discovered a phenomenon that we call “receptor pleiotropism” in which agonist antibodies against known receptors induce cell fates that are very different from those induced by the natural agonist to the same receptor

A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

SY Kim , J-W Theunissen , J Balibalos , S Liao-Chan , MC Babcock , T Wong , B Cairns , D Gonzalez , EH van der Horst , M Perez , Z Levashova , L Chinn , JA D‘Alessio , M Flory , A Bermudez , DY Jackson , E Ha , J Monteon , MF Bruhns , G Chen, and T-S Migone

Citation: Blood Cancer Journal (2015) 5, e316; doi:10.1038/bcj.2015.39 Published online 29 May 2015

Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin’s lymphoma.

Effects of Perivitelline Fluid Obtained from Horseshoe Crab on The Proliferation and Genotoxicity of Dental Pulp Stem Cells

Marahaini Musa, M.Sc,1 Khadijah Mohd Ali, B.Sc,1 Thirumulu Ponnuraj Kannan, Ph.D,1,2,* Ahmad Azlina, Ph.D,1 Nor Shamsuria Omar, M.Sc,1,3 Anil Chatterji, Ph.D,4 and Khairani Idah Mokhtar, Ph.D5

Cell J. 2015 Summer; 17(2): 253–263.

This is an in vitro experimental study. PVF samples were collected from horseshoe crabs from beaches in Malaysia and the crude extract was prepared. DPSCs were treated with different concentrations of PVF crude extract in an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (cytotoxicity test). We choose two inhibitory concentrations (IC50 and IC25) and two PVF concentrations which produced more cell viability compared to a negative control (100%) for further tests.

Potential Small Guide RNAs for tRNase ZL from Human Plasma, Peripheral Blood Mononuclear Cells, and Cultured Cell Lines

Sho Ninomiya , Mitsuoki Kawano, Takashi Abe , Tatsuya Ishikawa , Masayuki Takahashi , Masato Tamura , Yoshiaki Takahashi , Masayuki Nashimoto

PLoS ONE Published March 2, 2015

Several pieces of evidence suggest that small RNA degradation products together with tRNase ZL appear to form another layer of the whole gene regulatory network. The degraded RNA such as a 5′-half-tRNA and an rRNA fragment function as small guide RNA (sgRNA) to guide the enzyme to target RNA.

A phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia

Jeffrey E. Lancet, Gail J. Roboz, Larry D. Cripe, Glenn C. Michelson, Judith A. Fox, Richard D. Leavitt, Tianling Chen, Rachael Hawtin, Adam R. Craig, Farhad Ravandi, Michael B. Maris, Robert K. Stuart, and Judith E. Karp

Haematologica. 2014; 99:xxx doi:10.3324/haematol.2014.114769

Vosaroxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. This study assessed the safety and tolerability of vosaroxin plus cytarabine in patients with relapsed/refractory acute myeloid leukemia. Escalating vosaroxin doses (10-minute infusion; 10-90 mg/m2; days 1, 4) were given in combination with cytarabine on 1 of 2 schedules: schedule A (24-hour continuous intravenous infusion, 400 mg/m2/day, days 1-5) or schedule B (2-hour intravenous infusion,1 g/m2/day, days 1-5).

TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins

Ju Shi, Eileen L. Rose, Andrew Singh, Sami Hussain, Nancy E. Stagliano, Graham C. Parry, and Sandip Panicker

J Shi, EL Rose, A Singh, S Hussain… - 2014 - dnl-epi02.prodno.osl.basefarm.net

Here we test the effects of TNT003, amouse monoclonal antibody targeting the CP-specific serine protease C1s, on CP activity induced by cold agglutininson human RBCs.

Sign Up for Our Newsletter

Stay current with AllCells. Get email updates with helpful resources for biomedical researchers:

Have a question? Let’s chat.